Polyfunctional pyrazoles. 9. Synthesis of 1-alkyl(aryl)-3-[4-(hydroxymethyl)-1h-pyrazol-3-yl]ureas by Bratenko, M.K. et al.
0009-3122/14/5009-1252©2014 Springer Science+Business Media New York 1252 
Chemistry of Heterocyclic Compounds, Vol. 50, No. 9, December, 2014 (Russian Original Vol. 50, No. 9, September, 2014) 
 
POLYFUNCTIONAL PYRAZOLES. 9*. SYNTHESIS 
OF 1-ALKYL(ARYL)-3-[4-(HYDROXYMETHYL)- 
1Н-PYRAZOL-3-YL]UREAS 
 
M. K. Bratenko1**, M. M. Barus1, D. V. Rotar1, and M. V. Vovk2 
 
We have developed an effective method for the preparation of 1-alkyl(aryl)-3-[4-(hydroxymethyl)-
1Н-pyrazol-3-yl]ureas based on the interaction of 4-hydroxymethylpyrazole-3-carbonyl azides with 
primary aliphatic and aromatic amines under the conditions of Curtius reaction. In the absence of 
amines in the reaction mixture, in situ generated 4-hydroxymethyl-3-isocyanatopyrazoles underwent 
intramolecular cyclization to pyrazolo[3,4-d][1,3]oxazin-6(4Н)-ones. The latter showed a tendency to 
form 1-alkyl(aryl)-3-[4-(hydroxymethyl)-1Н-pyrazol-3-yl]ureas in the presence of amines. 
 
Keywords: 4-hydroxymethylpyrazole-3-carbonyl azides, (pyrazol-3-yl)ureas, pyrazolo[3,4-d][1,3]ox-
azines, intramolecular cyclization. 
 
 Functionalized pyrazole derivatives containing a hydroxymethyl or ureide group are compounds of 
synthetic and biological importance. For example, 4-(hydroxymethyl)pyrazoles present interest as modulators of 
АМРА receptor [2], and are also used as building blocks for the design of nonsteroidal anti-inflammatory drugs 
[3] and antineoplastic agents [4]. At the same time, 3-ureidopyrazoles are characterized by antitumor [5], anti-
inflammatory properties [6], and inhibitory properties against some types of kinases [7, 8]. Besides that, such 
compounds serve as precursors to pharmacologically valuable pyrazolo[3,4-d]pyrimidines [9, 10]. Taking into 
account these data, we decided to combine the indicated fragments into new structures of pyrazole type, which 
could serve as potential biologically active compounds. 
Among 3-ureido-substituted pyrazoles, examples are currently known that are additionally 
functionalized at the ring position 4 with ethoxycarbonyl [7, 9, 10] or carboxy groups [8], and are obtained by 
adding alkyl- or arylisocyanates to the respective 4-aminopyrazoles. This approach to the synthesis of 
4-hydroxymethyl analogs appears less appropriate, because 3-amino-4-hydroxymethylpyrazoles are unknown in 
the literature, and even if such compounds were available, selectivity problems would arise when adding 
isocyanates to amino group. 
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 Due to this reason, to achieve our goals we explored an effective synthetic route that relied on simple 
transformations of previously described [11] ethyl 4-hydroxymethylpyrazole-3-carboxylates 1a-d. 
Hydrazinolysis of these starting materials in refluxing ethanol gave the hydrazides 2a-d, the interaction of 
which with sodium nitrite in a mixture of hydrochloric and acetic acids led to the pyrazoyl azides 3a-d,  
compounds that are stable at room temperature. According to 1Н NMR data, the obtained samples had an assay 
of 90-93%, and were used in further transformations without additional purification. 
 We established that heating of acyl azides 3a-d for 2 h in refluxing toluene with alkyl(aryl)amines 4a-i 
led to the formation of 1-substituted 3-[(4-hydroxymethyl)-1Н-pyrazol-3-yl]ureas 5a-l in 69-83% yields 
(method А). This reaction involved initial thermal Curtius rearrangement of pyrazoyl azides [12] to 
3-isocyanatopyrazoles А, which immediately reacted with the respective amines. Such an approach was recently 
used [13] for the preparation of 3-ureidopyrazoles, which did not contain nucleophilic functional groups at 
position 4 of the azole ring. The presence of the latter may have a certain impact on the reactivity of in situ 
generated isocyanates. Thus, the absence of amines in the reaction mixture enables intramolecular cyclization 
involving isocyanate and hydroxymethyl groups, leading to the formation of 1-substituted pyrazolo[3,4-
d][1,3]oxazin-6(4Н)-ones 6a-d, examples of a little known [14, 15] bisheterocyclic system. Compounds 6a-d 
are characterized by relative lability of the oxazine ring and may undergo ring opening upon interaction with the 
amines 4a,e,f,h in refluxing chloroform, forming the ureas 5a,g,j,k (method B). This fact points to the formation 
of target compounds 5 under the reaction conditions both through direct interaction of amines 4 with 
isocyanates А, as well as with oxazines 6. In general, the developed method allows to use a wide range of 
amines, which is important for systematic building of focussed libraries of target compounds useful for 
biological screening.  
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1–3a, 5a,b, 6a R = Me; 1–3b, 5с–i, 6b R = Ph; 1–3c, 5j,k, 6c R = 4-ClC6H4; 1–3d, 5l, 6d R = 4-MeC6H4; 
4a, 5a,c R1 = HO(CH2)2; 4b, 5d R1 = Me2N(CH2)2; 4c, 5b,e R1 = Me2N(CH2)3; 
4d, 5f R1 = 4-ClC6H4CH2; 4e, 5j,l R1 = 4-MeC6H4CH2; 4f, 5g R1 = 4-MeOC6H4CH2 
4g, 5h R1 = 4-MeOC6H4(CH2)2; 4h, 5k R1 = 4-MeC6H5; 4i, 5i R1=4-MeOC6H4 
 
 The structure and composition of the intermediate hydrazides 2а-d, pyrazolooxazines 6а-d, and also the 
target products 5а-l were reliably confirmed by elemental analysis, chromato-mass spectrometry, IR and NMR 
spectroscopy (Tables 1-4). 
 The bactericidal properties of compounds 5а-h were studied by double serial dilutions on test 
microorganisms S. aureus (АТСС 25923), E. сoli (АТСС 25922), B. subtilis (АТСС 8236F800), and 
C. albicans (АТСС 885-653), and moderate antimicrobial activity was found (Table 5). 
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TABLE 1. Physicochemical Characteristics of the Synthesized 
Compounds 2а-d, 5a-l, 6a-d 
 
Found, % —————— 
Calculated, % 
Com-
pound 
Empirical 
formula С H N 
Mp, °С Yield, % (method) 
 
2a 
 
C6H10N4O2 
 
42.64 
42.35 
 
6.08 
5.92 
 
32.70 
32.94 
 
159-160 
 
84 
2b C11H12N4O2 56.58 
56.89 
5.34 
5.21 
24.31 
24.12 
94-95 93 
2c C11H11ClN4O2 49.31 
49.54 
4.29 
4.16 
21.17 
21.01 
161-162 90 
2d C12H14N4O2 58.75 
58.53 
5.52 
5.73 
23.01 
22.75 
130-131 89 
5a C8H14N4O3 42.03 
44.85 
6.74 
6.59 
26.17 
26.15 
139-140 60 (A) 
68 (B) 
5b C11H21N5O2 51.47 
51.75 
8.03 
8.29 
27.31 
27.43 
84-85 79 
5c C13H16N4O3 56.70 
56.51 
5.96 
5.84 
20.42 
20.28 
203-205 70 
5d C15H21N5O2 59.17 
59.39 
7.14 
6.98 
23.18 
23.09 
184-185 75 
5e C16H23N5O2 60.79 
60.55 
7.41 
7.30 
22.30 
22.07 
140-141 83 
5f C18H17ClN4O2 60.84 
60.59 
4.95 
4.80 
15.48 
15.70 
179-180 73 
5g C19H20N4O3 64.99 
64.74 
5.83 
5.72 
16.01 
15.90 
189-190 81 (A) 
83 (B) 
5h C20H22N4O3 65.81 
65.56 
5.78 
6.05 
15.42 
15.29 
179-180 69 
5i C18H18N4O3 64.20 
63.89 
5.32 
5.36 
16.47 
16.56 
184-185 72 
5j C19H19ClN4O2 61.41 
61.54 
5.32 
5.16 
14.97 
15.11 
193-194 71 (A) 
79 (B) 
5k C18H17ClN4O2 60.41 
60.59 
4.71 
4.80 
15.89 
15.70 
201-203 69 (A) 
76 (B) 
5l C20H22N4O2 68.31 
68.55 
6.50 
6.33 
16.11 
15.99 
174-175 72 
6a C6H7N3O2 46.81 
47.06 
4.69 
4.61 
27.58 
27.44 
213-215 63 
6b C11H9N3O2 61.64 
61.39 
4.11 
4.22 
19.33 
19.52 
184-185 59 
6c C11H8ClN3O2 53.21 
52.92 
3.27 
3.23 
16.92 
16.83 
218-220 67 
6d C12H11N3O2 62.59 
62.87 
4.99 
4.84 
18.28 
18.33 
201-202 62 
  
 
 Thus, we have established that ethyl 4-hydroxymethylpyrazole-3-carboxylates may act as effective 
substrates in the synthesis of promising biologically active 1-alkyl(aryl)-3-[4-(hydroxymethyl)-1Н-pyrazol-
3-yl]ureas with the reaction proceeding through in situ generated 4-hydroxymethyl-3-isocyanatopyrazoles as 
intermediates. 
 
 
EXPERIMENTAL 
 
 IR spectra were recorded on a UR-20 spectrometer in KBr pellets. 1Н and 13С NMR spectra were acquired 
on a Bruker Avance DRX-500 instrument (500 and 125 MHz, respectively) in DMSO-d6, with TMS as internal 
standard. Mass spectra were recorded on an Agilent LC/MSD SL system; Zorbax SB-C18 column, 4.6 × 15 mm, 
1.8 μm (PN 82(c)75-932); solvents: A – MeCN–Н2О (95:5), 0.1% trifluoroacetic acid, B – 0.1% aqueous 
trifluoroacetic acid; flow rate 3 ml/min; injection volume – 1 μl; UV detectors: 215, 254, 285 nm; 
 
 
 1254 
TABLE 2. 1Н NMR Spectra of Compounds 2a-d, 5a-l, 6a-d 
 
Com-
pound Chemical shifts, δ, ppm (J, Hz) 
 
2a 
 
3.83 (3H, s, CH3); 4.41 (2H, br. s, NH2); 4.53 (2H, s, CH2); 5.20 (1H, br. s, OH); 
7.65 (1H, s, H-5); 9.33 (1H, br. s, NH) 
2b 4.52 (2H, br. s, NH2); 4.64 (2H, s, CH2); 5.24-5.28 (1H, m, OH); 
7.33 (1Н, t, J = 6.8, H Ph); 7.51 (2Н, t, J = 7.2, H Ph); 7.91 (2Н, d, J = 7.6, H Ph); 
8.44 (1H, s, H-5); 9.64 (1H, br. s, NH) 
2с 4.49 (2H, s, NH2); 4.63 (2Н, d, J = 4.8, CH2); 5.28 (1Н, t, J = 4.6, OH); 
7.57 (2Н, d, J = 8.4, H Ar); 7.96 (2Н, d, J = 8.4, H Ar); 8.46 (1H, s, H-5); 
9.69 (1H, s, NH) 
2d 2.33 (3H, s, CH3); 4.48 (2H, s, NH2); 4.62 (2Н, d, J = 5.2, CH2); 5.27 (1Н, t, J = 5.2, OH); 
7.30 (2Н, d, J = 8.0, H Ar); 7.79 (2Н, d, J = 8.0, H Ar); 8.38 (1H, s, H-5); 9.60 (1H, s, NH) 
5a 3.17-3.23 (2H, m, CH2); 3.40-3.45 (2H, m, CH2); 3.68 (3H, s, CH3); 
4.22 (2Н, d, J = 5.2, CH2); 4.80 (2H, br. s, OH); 7.36 (1H, br. s, NH); 7.46 (1H, s, NH); 
8.18 (1H, s, H-5) 
5b 1.52-1.57 (2H, m, CH2); 2.11 (6H, s, 2CH3); 2.21 (2Н, t, J = 6.8, CH2); 
3.13 (2Н, q, J = 6.4, CH2); 3.68 (3H, s, CH3); 4.20 (2H, s, CH2); 4.80 (1H, br. s, ОН); 
7.35 (1H, br. s, NH); 7.40 (1H, s, NH); 8.11 (1H, s, H-5) 
5c 3.22-3.29 (2H, m, CH2); 3.50-3.56 (2H, m, CH2); 4.39 (2Н, d, J = 5.2, CH2); 
4.82-4.85 (1H, m, OH); 4.99 (1Н, t, J = 5.2, OH); 7.22 (1Н, t, J = 7.6, H Ph); 
7.44 (2Н, t, J = 8.2, H Ar); 7.74 (2Н, d, J = 8.0, H Ph); 8.02 (1H, br. s, NH); 8.32 (1H, s, H-5); 
8.54 (1H, s, NH) 
5d 2.23 (6H, s, 2CH3); 2.40-2.45 (2H, m, CH2); 3.29-3.34 (2H, m, CH2); 
4.39 (2Н, d, J = 5.4, CH2); 4.99 (1Н, t, J = 5.4, OH); 7.20-7.47 (3H, m, H Ph); 
7.79 (2Н, d, J = 7.0, H Ar); 8.23 (1H, br. s, NH); 8.33 (1H, s, H-5); 8.56 (1H, s, NH) 
5e 1.58-1.65 (2H, m, CH2); 2.10 (6H, s, 2CH3); 2.27 (2Н, t, J = 6.8, CH2); 
3.22 (2Н, q, J = 6.8, CH2); 4.37 (2H, s, CH2); 5.00 (1H, br. s, OH); 
7.22 (1Н, t, J = 7.6, H Ph); 7.45 (2Н, t, J = 7.8, H Ph); 7.54 (1H, br. s, NH); 
7.72 (2Н, d, J = 8.0, H Ph); 8.32 (1H, s, H-5); 8.49 (1H, br. s, NH) 
5f 4.38 (2H, s, CH2); 4.42 (2Н, d, J = 4.4, CH2); 5.00 (1Н, t, J = 4.4, OH); 
7.22-7.47 (7H, m, H Ar); 7.70 (2Н, d, J = 8.0, H Ar); 8.04 (1H, br. s, NH); 
8.32 (1H, s, H-5); 8.64 (1H, s, NH) 
5g 3.73 (3H, s, CH3O); 4.32 (2Н, d, J = 7.6, CH2); 4.98 (2Н, d, J = 5.2, CH2); 
4.99 (1Н, t, J = 5.2, OH); 6.91 (2Н, d, J = 8.4, H Ar); 7.26 (1Н, t, J = 7.6, H Ar); 
7.30 (2Н, d, J = 8.0, H Ar); 7.42 (2Н, t, J = 7.8, H Ar); 7.66 (2Н, d, J = 8.4, H Ar); 
8.02 (1H, br. s, NH); 8.32 (1H, s, H-5); 8.61 (1H, s, NH)  
5h 2.73 (2Н, d, J = 6.0, CH2); 3.45 (2Н, q, J = 6.0, CH2); 3.67 (3H, s, CH3O); 
4.36 (2Н, d, J = 5.6, CH2); 4.99 (1Н, t, J = 5.6, OH); 6.84 (2Н, d, J = 8.0, H Ar); 
7.17-7.28 (3H, m, H Ar); 7.41-7.56 (5H, m, H Ar, NH); 8.28 (1H, s, H-5); 
8.52 (1H, s, NH) 
5i 3.70 (3H, s, CH3O); 4.42 (2Н, d, J = 5.0, CH2); 4.96 (1Н, t, J = 5.0, OH); 
6.86 (2Н, d, J = 8.0, H Ar); 7.25 (1Н, t, J = 7.6, H Ar); 7.29 (2Н, d, J = 8.0, H Ar); 
7.40 (2Н, t, J = 7.8, H Ar); 7.60 (2Н, d, J = 8.2, H Ar); 8.31 (1H, s, H-5); 
8.57 (1H, s, NH); 9.32 (1H, s, NH) 
5j 2.26 (3H, s, CH3); 4.40 (2Н, d, J = 6.0, CH2); 4.64 (2Н, d, J = 5.6, CH2); 
5.23 (1Н, t, J = 5.6, OH); 7.11 (2Н, d, J = 8.0, H Ar); 7.22 (2Н, d, J = 8.0, H Ar); 
7.58 (2Н, d, J = 8.4, H Ar); 7.96 (2Н, d, J = 8.4, H Ar); 8.36 (1H, s, H-5); 
8.96 (1Н, t, J = 6.0, NH); 9.30 (1H, s, NH) 
5k 2.46 (3H, s, CH3); 4.40 (2Н, d, J = 4.8, CH2); 4.98 (1Н, t, J = 4.8, OH); 
7.09 (2Н, d, J = 8.0, H Ar); 7.36 (2Н, d, J = 8.0, H Ar); 7.53 (2Н, d, J = 8.4, H Ar); 
8.00 (2Н, d, J = 8.4, H Ar); 8.38 (1H, s, H-5); 8.74 (1H, s, NH); 9.36 (1Н, s, NH) 
5l 2.26 (3H, s, CH3); 2.34 (3H, s, CH3); 4.40 (2Н, d, J = 6.0, CH2); 
4.64 (2Н, d, J = 5.2, CH2); 5.22 (1Н, t, J = 6.0, OH); 7.12 (2Н, d, J = 8.0, H Ar); 
7.21 (2Н, d, J = 8.0, H Ar); 7.30 (2Н, d, J = 8.0, H Ar); 7.80 (2Н, d, J = 8.0, H Ar); 
8.39 (1H, s, H-5); 8.90 (1Н, t, J = 6.0, NH) 
6a 3.68 (3H, s, CH3); 5.24 (2H, s, CH2); 7.41 (1H, s, H-3); 10.34 (1H, s, NH) 
6b 5.38 (2H, s, CH2); 7.22 (1H, t, J = 8.8, H Ph); 7.46 (2H, t, J = 8.6, H Ph); 
7.67 (2Н, d, J = 8.8, H Ph); 8.48 (1H, s, H-3); 10.72 (1H, s, NH) 
6c 5.38 (2H, s, CH2); 7.49 (2Н, d, J = 7.5, H Ar); 7.69 (2Н, d, J = 7.5, H Ar); 
8.26 (1H, s, H-3); 10.77 (1H, s, NH) 
6d 2.30 (3H, s, CH3); 5.37 (2H, s, CH2); 7.25 (2Н, d, J = 7.8, H Ar); 
7.56 (2Н, d, J = 7.8, H Ar); 8.18 (1H, s, H-3); 10.69 (1H, s, NH) 
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TABLE 3. IR and Mass Spectra of Compounds 2a-d, 5a-l, 6a-d 
 
IR spectrum, ν, cm–1 IR spectrum, ν, cm–1 Com-
pound С=О NH OH 
Mass 
spectrum, 
m/z [M+H]+ 
Com-
pound С=О NH OH 
Mass 
spectrum, 
m/z [M+H]+ 
 
2а 
 
1680 
 
3340 
 
3420 
 
171 
 
5g 
 
1685 
 
3275 
 
3460 
 
353 
2b 1680 3315 3415 233 5h 1695 3280 3480 367 
2c 1685 3340 3425 267 5i 1675 3285 3470 339 
2d 1685 3340 3420 247 5j 1685 3270 3470 371 
5a 1695 3280 3478 215 5k 1675 3285 3475 357 
5b 1690 3280 3460 256 5l 1685 3280 3480 351 
5c 1695 3265 3480 277 6a 1735 3230  154 
5d 1695 3270 3475 304 6b 1730 3240  216 
5e 1690 3270 3465 318 6c 1735 3235  250 
5f 1685 3265 3480 357 6d 1730 3235  230 
  
 
TABLE 4. 13С NMR Spectra of Compounds 6a-d 
 
Chemical shifts, δ, ppm Com-
pound С-3 C-3a C-4 C-6 C-7a R 
 
6a 
 
121.7 
 
101.2 
 
63.8 
 
150.3 
 
147.0 
 
39.2 
6b 122.5 100.4 64.3 150.4 148.1 119.8; 128.2; 129.7; 139.6 
6c 122.9 100.9 64.1 150.4 148.4 118.7; 129.4; 129.8; 138.4 
6d 122.6 100.4 64.2 150.5 148.2 23.3; 119.2; 127.3; 130.3; 137.6 
  
 
TABLE 5. The Minimum Bacteriostatic (MIC), Bactericidal (MBC), 
Fungostatic (MIC), and Fungicidal (MFC) Concentrations (μg/ml) 
 
Test microorganism 
S. aureus 
АТСС 25923 
E. coli 
АТСС 25922 
B. subtilis 
АТСС 8236F800 
C. albicans 
АТСС 885-653 Compound 
MIC MBC MIC MBC MIC MBC MIC MFC 
 
1, 6 а,b, 5a–h 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
 
250 
2a 250 250 125 250 125 250 125 250 
2b 250 250 125 250 250 250 250 250 
Furacilin 1.95 7.8 3.9 7.8 1.95 7.8 1.95 3.9 
  
 
 
CI at atmospheric pressure, m/z scanning range 80-1000. Elemental analysis was performed on a Perkin Elmer 
CHN Analyzer at the analytical laboratory of the Institute of Organic Chemistry, National Academy of Sciences 
of Ukraine. Melting points were determined on a Kofler hot bench and were not corrected. 
 Compounds 1а-d were synthesized according to a published method [11]. 
 Compound 1а. Yield 72%. Mp 59-60°С (EtOH). IR spectrum, ν, cm-1: 1720 (С=О), 3460 (ОН). 
1H NMR spectrum, δ, ppm (J, Hz): 1.27 (3Н, t, J = 7.2, СН3); 3.87 (3Н, s, ОСН3); 4.23 (2Н, q, J = 7.2, ОСН2); 
4.57 (2Н, d, J = 6.4, СН2); 4.98 (1Н, t, J = 6.4, ОН); 7.98 (1Н, s, Н-5). Found, %: С 52.36; Н 6.67; N 15.51. 
С8Н12N2О3. Calculated, %: С 52.17; Н 6.57; N 15.21. 
 Preparation of 4-(Hydroxymethyl)-1-methyl(aryl)-1Н-pyrazole-3-carbohydrazides 2а-d (General 
Method). A solution of ester 1а-d (0.02 mol) in EtOH (30 ml) was treated with 99% NH2NH2·H2O (1 g, 
0.02 mol). The mixture was refluxed for 5 h, cooled, the solvent was removed, the residue was crystallized from 
ЕtОН. 
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 Preparation of 4-(Hydroxymethyl)-1-methyl(aryl)-1Н-pyrazole-3-carbonyl Azides 3а-d (General 
Method). A solution of NaNO2 (1.38 g, 0.02 mol) in H2O (10 ml) was added with stirring and cooling (5°С) to 
a solution of hydrazide 2а-d (0.015 mol) in AcOH (25 ml) and conc. HCl (1.5 ml). The reaction mixture was 
stirred for 1 h at this temperature, then for 1 h at room temperature, poured into ice water (100 ml), and 
maintained for 1 h at 5°С. The precipitate was filtered off, washed with ice water (2×30 ml), and dried in 
vacuum desiccator over Р2О5. Yield 68-75%. The products were used without additional purification for the 
synthesis of compounds 5а-l and 6а-d. 
 Preparation of 2-Methyl(aryl)-2,7-dihydropyrazolo[3,4-d][1,3]oxazin-6(4Н)-ones 6а-d (General 
Method). A solution of azide 3а-d (0.011 mol calculated for 90% assay) in anhydrous toluene (30 ml) was 
refluxed for 3 h; solvent was removed by distillation to 1/4 of the starting volume and the residue was cooled to 
room temperature. The precipitate formed was filtered off, washed with 1:1 mixture of toluene–hexane (20 ml), 
dried, and crystallized from toluene. 
 Preparation of 1-Alkyl(aryl)-3-[4-(hydroxymethyl)-1Н-pyrazol-3-yl]ureas 5а-l (General Method). 
А. Amine 4а-і (0.01 mol) in toluene (5 ml) was added to a solution of azide 3а-d (0.01 mol calculated for 90% 
assay) in anhydrous toluene (25 ml) and the mixture was refluxed for 1 h. The solvent was removed by 
distillation, the residue was crystallized from a 2:1 mixture of EtOH–АсOH. 
 B. Amine 4a,e,f,h (0.005 mol) in CHCl3 (5 ml) was added to a solution of pyrazolooxazinone 6а-d 
(0.005 mol) in CHCl3 (10 ml) and the mixture was refluxed for 2 h. The solvent was removed by evaporation, 
the residue was crystallized from a 2:1 mixture of EtOH–АсOH. 
 Antimicrobial activity against standard lines of S. aureus (АТСС 25923), E. сoli (АТСС 25922), 
B. subtilis (АТСС 8236F800), and C. albicans (АТСС 885-653) was determined in liquid broth with four-hour 
inoculation of test culture determined to contain 1-2 million cells per 1 ml according to calibration curve. The 
results were collected after 24 h incubation at 37°С, or 48 h at 28°С in the case of fungal cultures. The MIC 
values were established as the highest dilution that suppressed the growth and multiplication of microorganisms. 
The MBC and MFC values were established by inoculating bacteriological droplets from test tubes free of 
visually observed microbial growth on Petri dish sectors containing beef peptone agar (for bacteria) or Saburo 
medium (for fungi). Bacteria were incubated for 2 days at 37°С, fungi – for 4 days at 28°С. The sector 
containing the minimum concentration that lacked microbial growth was interpreted as containing the minimum 
bactericidal concentration [16]. 
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